Literature DB >> 12963646

Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow.

Stephen M Black1, Eugenia Mata-Greenwood, Robert W Dettman, Boaz Ovadia, Robert K Fitzgerald, Olaf Reinhartz, Stefan Thelitz, Robin H Steinhorn, Rene Gerrets, Karen Hendricks-Munoz, Gregory A Ross, Janine M Bekker, Michael J Johengen, Jeffrey R Fineman.   

Abstract

BACKGROUND: Endothelin-1 (ET-1) has been implicated in the pathophysiology of pulmonary hypertension. In 1-month-old lambs with increased pulmonary blood flow, we have demonstrated early alterations in the ET-1 cascade. The objective of this study was to investigate the role of potential later alterations of the ET cascade in the pathophysiology of pulmonary hypertension secondary to increased pulmonary blood flow. METHODS AND
RESULTS: Eighteen fetal lambs underwent in utero placement of an aortopulmonary vascular graft (shunt) and were studied 8 weeks after spontaneous delivery. Compared with age-matched control lambs, lung tissue ET-1 levels were increased in shunt lambs (317.2+/-113.8 versus 209.8+/-61.8 pg/g, P<0.05). In shunt lambs (n=9), exogenous ET-1 induced potent pulmonary vasoconstriction, which was blocked by the ETA receptor antagonist PD 156707 (n=3). This pulmonary vasoconstriction was mimicked by exogenous Ala1,3,11,15 ET-1 (4 Ala ET-1), the ETB receptor agonist, and was blocked by the ETB receptor antagonist BQ 788 (n=3). However, in control lambs (n=7), ET-1 and 4 Ala ET-1 did not change pulmonary vascular tone. In contrast to 4-week-old shunt lambs, immunohistochemistry revealed the emergence of ETB receptors on smooth muscle cells in the vasculature of 8-week-old shunt lambs.
CONCLUSIONS: Over time, increased pulmonary blood flow and/or pressure results in the emergence of ETB-mediated vasoconstriction, which coincides with the emergence of ETB receptors on smooth muscle cells. These data suggest an important role for ETB receptors in the pathophysiology of pulmonary hypertension in this animal model of increased pulmonary blood flow.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963646     DOI: 10.1161/01.CIR.0000087596.01416.2F

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  Oxidative stress and the development of endothelial dysfunction in congenital heart disease with increased pulmonary blood flow: lessons from the neonatal lamb.

Authors:  Saurabh Aggarwal; Christine Gross; Jeffrey R Fineman; Stephen M Black
Journal:  Trends Cardiovasc Med       Date:  2010-10       Impact factor: 6.677

2.  Contrasting effects of intervention with ETA and ETB receptor antagonists in hypertension induced by angiotensin II and high-salt diet.

Authors:  Erika I Boesen; Jennifer S Pollock; David M Pollock
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

Review 3.  Pulmonary hypertension complicating congenital heart disease.

Authors:  J Eduardo Rame
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 4.  Ambrisentan: a review of its use in pulmonary arterial hypertension.

Authors:  Belinda N Rivera-Lebron; Michael G Risbano
Journal:  Ther Adv Respir Dis       Date:  2017-04-20       Impact factor: 4.031

5.  Endogenous endothelin stimulates cardiac sympathetic afferents during ischaemia.

Authors:  Liang-Wu Fu; Zhi-Ling Guo; John C Longhurst
Journal:  J Physiol       Date:  2010-05-04       Impact factor: 5.182

6.  Changing standard chow diet promotes vascular NOS dysfunction in Dahl S rats.

Authors:  Frank T Spradley; Dao H Ho; Kyu-Tae Kang; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-26       Impact factor: 3.619

7.  Inhibitory effect of ETB receptor on Na(+)-K(+) ATPase activity by extracellular Ca(2+) entry and Ca(2+) release from the endoplasmic reticulum in renal proximal tubule cells.

Authors:  Yan Liu; Jian Yang; Hongmei Ren; Duofen He; Annabelle Pascua; M Ines Armando; Chengming Yang; Lin Zhou; Robin A Felder; Pedro A Jose; Chunyu Zeng
Journal:  Hypertens Res       Date:  2009-08-07       Impact factor: 3.872

8.  Disruption of endothelial cell mitochondrial bioenergetics in lambs with increased pulmonary blood flow.

Authors:  Xutong Sun; Shruti Sharma; Sohrab Fratz; Sanjiv Kumar; Ruslan Rafikov; Saurabh Aggarwal; Olga Rafikova; Qing Lu; Tantiana Burns; Sridevi Dasarathy; Johnny Wright; Christian Schreiber; Monique Radman; Jeffrey R Fineman; Stephen M Black
Journal:  Antioxid Redox Signal       Date:  2013-03-14       Impact factor: 8.401

9.  Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

Authors:  David M Pollock; Erika I Boesen; Stephen M Black
Journal:  Mol Interv       Date:  2009-04

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.